It is dispensed in amber multidose vials containing 1,000 mcg/mL and compounded for use under either section 503A or 503B, allowing clinicians to individualize therapy for deficiency states ranging from pernicious anemia to postsurgical malabsorption
However, the longer a therapy continues, the higher and higher the likelihood of improvement regardless of circumstance, especially in an illness with as much natural variability as ME/CFS
doi:10.1126/sciadv.aax6328
CJC-1295 is a synthetic analogue of Growth Hormone-Releasing Hormone (GHRH) with tetrasubstituted modifications (D-Ala, Gln, Ala, Leu) that protect the peptide from degradation by the enzyme DPP-IV, thereby extending its half-life relative to native GHRH
[DOI] [PMC free article] [PubMed] [Google Scholar] [136].Cheng Y, Xu T, Li S, Ruan H, GPX1, a biomarker for the diagnosis and prognosis of kidney cancer, promotes the progression of kidney cancer